Images List Premium Download Classic

Metabolic Syndrome

Metabolic Syndrome-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods ...
Volant Holdings Gmbh
June 22, 2017 - N°20170173060

In one embodiment, the invention provides a method of regenerating organs and tissues in a subject suffering from one or more organ or tissue manifestations of glucose supply side associated metabolic syndrome, the method comprising: (a) confirming that the subject suffers from or is at risk for suffering from organ and/or tissue damage associated with a glucose supply side ...
NEW Methods for treating visceral fat conditions
Orexigen Therapeutics, Inc.
June 22, 2017 - N°20170172999

Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion.
Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
Berg Llc
June 15, 2017 - N°20170166891

The invention provides methods of treatment of metabolic syndrome with hsp90 inhibitors, particularly hsp90β inhibitors. The invention provides methods of diagnosis and monitoring of metabolic syndrome using hsp90, particularly hsp90β, expression and activity level.
Metabolic Syndrome Patent Pack
Download + patent application PDFs
Metabolic Syndrome Patent Applications
Download + Metabolic Syndrome-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Metabolic Syndrome-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same
Illinois Institute Of Technology
June 15, 2017 - N°20170165211

The present invention relates to a modified taurine, and a pharmaceutical composition for preventing or treating metabolic disease or a food composition, which contains the modified taurine as an active ingredient. More specifically, the modified taurine of the present invention has physical properties different from those of existing taurine, and has significant effects on the prevention and treatment of metabolic ...
Novel lactic acid bacteria and use thereof
New Bellus Enterprises Co., Ltd.
June 08, 2017 - N°20170157183

The present invention discloses novel lactic acid bacteria, which are isolated lactococcus lactis subsp. Lactis ll358 and isolated lactobacillus salivarius ls159 respectively. By administering the novel lactic acid bacteria of the present invention, renal injury, metabolic syndrome, hyperuricemia, hypocalcemia, and other disorders can be effectively ameliorated or treated.
Crystalline solvate forms of a pharmaceutical
Neurmedix, Inc.
June 01, 2017 - N°20170152281

The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include form i anhydrate and form iv and form v solvates. The invention further relates to solid ...
Metabolic Syndrome Patent Pack
Download + patent application PDFs
Metabolic Syndrome Patent Applications
Download + Metabolic Syndrome-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Metabolic Syndrome-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Calcitonin mimetics for treating diseases and disorders
New York University
May 25, 2017 - N°20170143800

Calcitonin mimetic peptides having an amino acid sequence in accordance with seq id no:8 or seq id no:53, each of which may be carboxylated at its n-terminal or otherwise modified to reduce the positive charge of the first amino acid and independently of that may be amidated at its c-terminal, and in each of which the 1 and 7 position cysteine residues ...
Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
The General Hospital Corporation
May 18, 2017 - N°20170136095

Methods of treating obesity, metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes using a pentapeptide, lvkgramide, derived from the c-terminus of glucagon-like peptide 1 (glp-1).
Methods and compositions for treating metabolic syndrome
The General Hospital Corporation
May 18, 2017 - N°20170136032

Or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein , l, r1, r2, z, x, a and b are defined herein.
Method of treating hyperlipidemia and atherosclerosis with mir-30c
The Research Foundation For The State University Of New York
May 04, 2017 - N°20170121713

This disclosure provides a novel role for microrna (mir) regulation of lipid metabolism via the mtp pathway, leading to reductions in apob secretion and blood lipid levels. Mir regulation of the mtp pathway is shown herein to reduce hyperlipidemia and atherosclerosis in vivo. Therefore, inhibition of mtp expression and activity by mir regulation is identified as a new therapeutic target ...
Ppar modulators
FundaÇao Universidade De BrasÍlia
May 04, 2017 - N°20170121268

The present application relates to amorfrutin analogs and uses as ppar modulators for the treatment of metabolic syndrome, obesity, hyperlipidemia, elevated fasting blood glucose, elevated blood pressure, low hdl cholesterol, type 2 diabetes, cardiovascular disease, a neurodegenerative disease, malaria or irritable bowel syndrome.
Methods for treating obesity and/or metabolic syndrome
Mesoblast, Inc.
May 04, 2017 - N°20170119822

The present disclosure provides methods of treating or preventing obesity or causing weight loss or treating or preventing metabolic syndrome comprising administering to a subject a population of cells enriched for stro-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
Compounds influencing fatty acid uptake and metabolism and the production of inflammatory agents and methods ...
The Hershey Company
May 04, 2017 - N°20170119729

The invention provides compounds and plant extract compositions that inhibit pancreatic enzymes, such as lipases and amylases, and most particularly pancreatic lipase and phospholipase a2 (pla2), and cox-2 enzyme, and improve the inflammatory state or response conditions in animals. The compounds and plant extracts can be used in methods and administration regimens to treat animals for obesity-related conditions, diabetes and ...
Metabolic Syndrome Patent Pack
Download + patent application PDFs
Metabolic Syndrome Patent Applications
Download + Metabolic Syndrome-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Metabolic Syndrome-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel biological detection method for dioxins in serum, and a diagnostic use therefor in metabolic ...
University-industry Cooperation Group Of Kyung Hee
April 20, 2017 - N°20170107584

The present invention relates to a novel biological detection method for dioxins in serum and a diagnostic use thereof in metabolic syndrome and related conditions. More particularly, according to the present invention, a significant correlation between dioxin content in serum and physical variables has been confirmed by measuring luciferase activity through the use of serum as a whole and cells ...
Composition for preventing and treating non-alcoholic fatty liver diseases
Jbk Natural Medicine Institute
April 20, 2017 - N°20170106035

A composition includes a black chokeberry extract and at least one of a thistle extract, a black hoof mushroom extract and a mixture thereof. The composition is effective in preventing and treating non-alcoholic fatty liver disease caused by accumulation of fat in the liver due to excessive intake of nutrients or metabolic syndrome regardless of alcohol intake. The composition can ...
Activation of amp-protein activated kinase by oxaloacetate compounds
Jbk Natural Medicine Institute
April 20, 2017 - N°20170105954

The present invention relates to oxaloacetate compounds that activate amp-activated protein kinase (ampk), including the preparation of the compounds, compositions containing the compounds, preserving said compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, obesity, cardiovascular disease, alzheimer's disease, and cancer.
Chimeric fibroblast growth factor 19 proteins and methods of use
New York University
April 13, 2017 - N°20170101449

The present invention relates to a chimeric protein that includes an n-terminus coupled to a c-terminus, where the n-terminus includes a portion of a paracrine fibroblast growth factor (“fgf”) and the c-terminus includes a c-terminal portion of an fgf 19 molecule. The portion of the paracrine fgf is modified to decrease binding affinity for heparin and/or ...
Sweetness receptor antagonist
New York University
April 13, 2017 - N°20170101372

Wherein each symbol is described herein, are useful for the prophylaxis or treatment of metabolic syndrome, diabetes, obesity and the like.
Systems and methods of improving metabolic syndrome
Ohio State Innovation Foundation
April 13, 2017 - N°20170100604

Methods for improving metabolic syndrome in a subject are provided. Methods include positioning a therapy delivery device on a neural target site that contributes to immune activity of the subject. The therapy delivery device is activated to deliver a therapy signal to the neural target site to improve the subject's metabolic syndrome.
Peptide analogs for treating diseases and disorders
Keybioscience Ag
April 06, 2017 - N°20170096467

Provided herein are peptides, that in combination with metformin, are effective for the treatment of type i diabetes, type ii diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high ...
Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii ...
New York University
April 06, 2017 - N°20170096462

The present invention relates to chimeric proteins that include an n-terminus coupled to a c-terminus, where the n-terminus includes an n-terminal portion of fibroblast growth factor 21 (“fgf21”) and the c-terminus includes a c-terminal portion of fibroblast growth factor 19 (“fgf19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to ...
Loading